Back to Search Start Over

Transient MOG antibody seroconversion associated with immunomodulating therapy

Authors :
Frank Leypoldt
Markus Reindl
Leoni Rolfes
Sven Jarius
Klaus-Peter Wandinger
Christin Campe
Hans-Jochen Heinze
Brigitte Wildemann
Marc Pawlitzki
Peter Körtvelyessy
Source :
Multiple Sclerosis and Related Disorders 37, 101420 (2020). doi:10.1016/j.msard.2019.101420
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

Immunoglobulin G (IgG) autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) have recently been associated with autoimmune CNS demyelination. We present the case of a 35-year-old patient who was seronegative for MOG-IgG (as confirmed by means of three independent immunoassays) during two corticosteroid-responsive attacks of brainstem encephalitis and optic neuritis, respectively, but turned positive for MOG-IgG under treatment with interferon-beta (IFN-beta), which was commenced 6 months after onset of the first attack. MOG-IgG serum levels declined after therapy was switched to glatiramer acetate. The fact that seroconversion was first observed under treatment with IFN-beta is in accordance with previous evidence suggesting a role of IFN-beta in disease exacerbation in antibody-mediated disorders.

Details

ISSN :
22110348
Volume :
37
Database :
OpenAIRE
Journal :
Multiple Sclerosis and Related Disorders
Accession number :
edsair.doi.dedup.....816a8154cd44b763d9f1454ae08106e8
Full Text :
https://doi.org/10.1016/j.msard.2019.101420